Who is sponsoring NCT00755703?

NCT00755703 is sponsored by Altimmune, Inc..

What condition does NCT00755703 study?

NCT00755703 studies Influenza A Subtype H5N1 Infection.

What drugs are being tested in NCT00755703?

Interventions: Pandemic Influenza Vaccine, Placebo.

What is the status of NCT00755703?

NCT00755703 is currently COMPLETED.

Last reviewed 2025-05-24 · How we verify

A Phase I, Dose-Ranging Safety and Immunogenicity Study of an Adenovirus-vectored Intranasal, Pandemic (Hemagglutinin H5) Influenza Vaccine, ADhVN1203/04.H5, in Healthy Adults

NCT00755703 Phase 1 COMPLETED

The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe route for inducing protection in animals against pandemic influenza in preclinical studies. The vaccine is non-replicating, tissue culture based and designed for intranasal delivery.

Details

Lead sponsor	Altimmune, Inc.
Phase	Phase 1
Status	COMPLETED
Enrolment	48
Start date	2008-10
Completion	2011-12

Conditions

Influenza A Subtype H5N1 Infection

Interventions

Pandemic Influenza Vaccine
Placebo

Primary outcomes

To assess the safety of a nasally administered adenovirus-vectored pandemic influenza vaccine in healthy human adults. — 56 day observations with 2 year follow-up

Countries

United States